BioXcel Therapeutics (BTAI) Tops Q2 EPS by 50c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q2 EPS of ($0.21), $0.50 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $662.5 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• UBS sees a negative catalyst ahead for Nike: Here’s what to watch
• Scotiabank Reiterates Sector Outperform Rating on Pan American Silver Corp (PAAS:CN) (PAAS)
• Jackson Financial Inc. (JXN) call put ratio 1 call to 14.6 puts with a focus on September 130 and 135 puts as share price down 4.8%